WO2023076131A3 - Fonction du gène de l'herpèsvirus lié au sarcome de kaposi - Google Patents

Fonction du gène de l'herpèsvirus lié au sarcome de kaposi Download PDF

Info

Publication number
WO2023076131A3
WO2023076131A3 PCT/US2022/047515 US2022047515W WO2023076131A3 WO 2023076131 A3 WO2023076131 A3 WO 2023076131A3 US 2022047515 W US2022047515 W US 2022047515W WO 2023076131 A3 WO2023076131 A3 WO 2023076131A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral
kshv
gene function
factors
replication
Prior art date
Application number
PCT/US2022/047515
Other languages
English (en)
Other versions
WO2023076131A2 (fr
Inventor
Fenyong Liu
Adam Smith
Marco PALIZA-CARRE
Rachael Burchfield BURCHFIELD
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2023076131A2 publication Critical patent/WO2023076131A2/fr
Publication of WO2023076131A3 publication Critical patent/WO2023076131A3/fr
Priority to US18/629,922 priority Critical patent/US20240248080A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16051—Methods of production or purification of viral material
    • C12N2710/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16461—Methods of inactivation or attenuation
    • C12N2710/16462—Methods of inactivation or attenuation by genetic engineering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La fonction du gène de l'herpèsvirus lié au sarcome de Kaposi et des méthodes de développement d'antiviraux, de vaccins anti-KSHV et de vecteurs à base de KSHV, et des compositions.
PCT/US2022/047515 2021-10-25 2022-10-24 Fonction du gène de l'herpèsvirus lié au sarcome de kaposi WO2023076131A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/629,922 US20240248080A1 (en) 2021-10-25 2024-04-08 Kaposi sarcoma associated herpesvirus gene function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163271704P 2021-10-25 2021-10-25
US63/271,704 2021-10-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/629,922 Continuation US20240248080A1 (en) 2021-10-25 2024-04-08 Kaposi sarcoma associated herpesvirus gene function

Publications (2)

Publication Number Publication Date
WO2023076131A2 WO2023076131A2 (fr) 2023-05-04
WO2023076131A3 true WO2023076131A3 (fr) 2023-08-24

Family

ID=86159702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/047515 WO2023076131A2 (fr) 2021-10-25 2022-10-24 Fonction du gène de l'herpèsvirus lié au sarcome de kaposi

Country Status (2)

Country Link
US (1) US20240248080A1 (fr)
WO (1) WO2023076131A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037847A1 (en) * 1998-11-19 2004-02-26 Kieff Elliott D. Assays for compounds that modulate rhadino virus lana action in trans on a unit of rhadino virus dna to mediate efficient episome persistence
WO2005028634A2 (fr) * 2003-09-18 2005-03-31 Emory University Vaccins mva ameliores
KR20090074717A (ko) * 2009-06-25 2009-07-07 고려대학교 산학협력단 감마허피스바이러스 재활성 유도 천연화합물의 검색 리포터 시스템 및 이를 이용한 검색방법
US20180311343A1 (en) * 2016-10-26 2018-11-01 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2020172522A1 (fr) * 2019-02-22 2020-08-27 Ogembo Javier Gordon Particules multivalentes de type herpèsvirus associées au sarcome de kaposi (kshv) et leurs utilisations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037847A1 (en) * 1998-11-19 2004-02-26 Kieff Elliott D. Assays for compounds that modulate rhadino virus lana action in trans on a unit of rhadino virus dna to mediate efficient episome persistence
WO2005028634A2 (fr) * 2003-09-18 2005-03-31 Emory University Vaccins mva ameliores
KR20090074717A (ko) * 2009-06-25 2009-07-07 고려대학교 산학협력단 감마허피스바이러스 재활성 유도 천연화합물의 검색 리포터 시스템 및 이를 이용한 검색방법
US20180311343A1 (en) * 2016-10-26 2018-11-01 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
WO2020172522A1 (fr) * 2019-02-22 2020-08-27 Ogembo Javier Gordon Particules multivalentes de type herpèsvirus associées au sarcome de kaposi (kshv) et leurs utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Site directed mutagenesis kits, QuikChange II", AGILENT, 16 June 2021 (2021-06-16), XP093086983, Retrieved from the Internet <URL:https://www.agilent.com/en/product/mutagenesis-cloning/mutagenesis-kits/site-directed-mutagenesis-kits/quikchange-ii-233117?gad=1&gclid=CjwKCAjwyNSoBhA9EiwA5aYlb4kzJMOhkczlBTxfxpunmsS9OjXyDFJs60EJ0I_GVaimjisyXrsyeBoCbDIQAvD_BwE&gclsrc=aw.ds> [retrieved on 20230928] *
D. C. FREED, Q. TANG, A. TANG, F. LI, X. HE, Z. HUANG, W. MENG, L. XIA, A. C. FINNEFROCK, E. DURR, A. S. ESPESETH, D. R. CASIMIRO,: "Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 51, 17 December 2013 (2013-12-17), pages E4997 - E5005, XP055137188, ISSN: 00278424, DOI: 10.1073/pnas.1316517110 *
GALLO ANTONIO, LAMPE MELANIE, GÜNTHER THOMAS, BRUNE WOLFRAM: "The Viral Bcl-2 Homologs of Kaposi's Sarcoma-Associated Herpesvirus and Rhesus Rhadinovirus Share an Essential Role for Viral Replication", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 91, no. 6, 15 March 2017 (2017-03-15), US , XP093086980, ISSN: 0022-538X, DOI: 10.1128/JVI.01875-16 *
HWANG SUNG-WOO; KIM DONGIK; JUNG JAE U.; LEE HYE-RA: "KSHV-encoded viral interferon regulatory factor 4 (vIRF4) interacts with IRF7 and inhibits interferon alpha production", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 486, no. 3, 22 March 2017 (2017-03-22), Amsterdam NL , pages 700 - 705, XP029968967, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2017.03.101 *
LI, Q. ; ZHOU, F. ; YE, F. ; GAO, S.J.: "Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 379, no. 2, 30 September 2008 (2008-09-30), AMSTERDAM, NL , pages 234 - 244, XP024526304, ISSN: 0042-6822, DOI: 10.1016/j.virol.2008.06.043 *

Also Published As

Publication number Publication date
WO2023076131A2 (fr) 2023-05-04
US20240248080A1 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
Altfeld et al. Innate immunity against HIV-1 infection
Dunn et al. HijAkt: The PI3K/Akt pathway in virus replication and pathogenesis
Kotwal Microorganisms and their interaction with the immune system
EA201270632A1 (ru) 2&#39;-фтор-6&#39;-метилен карбоциклические нуклеозиды и способы лечения вирусных инфекций
EP4219696A3 (fr) Souche de virus oncolytique
WO2017161360A3 (fr) Vecteur multimodal pour l&#39;infection de cellules dendritiques
West et al. Toll-like receptor sensing of human herpesvirus infection
RU2015121828A (ru) Вакцины на основе рекомбинантных частиц против инфекции цитомегаловируса человека
Hopcraft et al. Tumour viruses and innate immunity
Trigg et al. Functions of DNA damage machinery in the innate immune response to DNA virus infection
Naqvi Immunomodulatory roles of human herpesvirus‐encoded microRNA in host‐virus interaction
Lange et al. Activation and evasion of innate immunity by gammaherpesviruses
Le‐Trilling et al. Attack, parry and riposte: molecular fencing between the innate immune system and human herpesviruses
WO2008048984A3 (fr) Procédés et compositions permettant de préparer un vaccin universel contre la grippe
WO2023076131A3 (fr) Fonction du gène de l&#39;herpèsvirus lié au sarcome de kaposi
Gale Jr et al. Viral evasion of the interferon system
Cristillo et al. Double-stranded RNA as a not-self alarm signal: to evade, most viruses purine-load their RNAs, but some (HTLV-1, Epstein-Barr) pyrimidine-load
MX2022016281A (es) Composiciones y metodos antivirales de amplio espectro.
AU2003255315A1 (en) Vaccinia virus host range genes to increase the titer of avipoxviruses
Freer et al. Virome and inflammasomes, a finely tuned balance with important consequences for the host health
Montagnaro et al. Bovine herpesvirus type 4 infection modulates autophagy in a permissive cell line
EP4331676A3 (fr) Vaccins viraux
Shao et al. Lack of resistance-associated mutations in UL54 and UL97 genes of circulating cytomegalovirus strains isolated in a medical center in Taiwan
WO2009146150A3 (fr) Recombinaison homologue virale et ses utilisations
Jang et al. Suppression of lytic replication of Kaposi’s sarcoma-associated herpesvirus by autophagy during initial infection in NIH 3T3 fibroblasts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22887985

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE